My name is Chelsea, and I will be your conference call facilitator this afternoon. At this time, I would like to welcome everyone to Envista Holdings Corporation's second quarter 2022 earnings results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, press star, then the number one on your telephone keypad. If you would like to withdraw your question, you may press the pound key on your telephone. I will now turn the call over to Mr. Stephen Keller, Vice President of Investor Relations of Envista Holdings. Mr. Keller, you may begin your conference call.
Hello, and thanks for joining us on the call. With us today are Amir Aghdaei, our President and Chief Executive Officer, and Howard Yu, our Chief Financial Officer. I wanna point out that our earnings release, the slide presentation supplementing today's call, and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the investor section of our website, www.envistaco.com. The audio portion of this call will be archived on the Investor section of our website later today under the heading Events and Presentations. It will remain archived until our next quarterly call. As announced on January 3rd, 2022, we have closed the acquisition of the KaVo Treatment Unit and Instruments business.
For the first and second quarters of 2022 and the full year of 2021, the results of this business are reflected as discontinued operations in our financial statements as required by generally accepted accounting principles. All references in these remarks and accompanying presentations to earnings, revenues, and other company-specific financial metrics relate only to continuing operations of Envista's business, except for cash flow measures. During the presentation, we will describe some of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, references in these remarks to company-specific financial metrics relate to second quarter of 2022, and references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices that have applications submitted and pending. Certain regulatory approvals are available only in certain markets.
During the call, we will make forward-looking statements within the meaning of the Federal Securities Law, including statements regarding events or developments that we believe, anticipate, or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they were made, and we do not assume any obligation to update any forward-looking statements except as required by law. With that, I'd like to turn the call over to Amir.
Thank you, Stephen, and welcome everyone to Envista's Q2 2022 earnings call. I want to start today's call by thanking our employees for delivering another solid quarter. Despite supply chain disruptions, accelerating inflation, and a severe COVID-related lockdown in China, our team delivered mid-single-digit core growth, expanded our adjusted EBITDA margins, and successfully integrated our newly acquired Intra-Oral Scanner (IOS) business. Our resilient performance is a testament to our strategic differentiation and our proven track record of execution. Before I turn it over to Howard to discuss our second quarter results in more detail, I want to reiterate our long-term vision, provide some insight on current market conditions, and offer a quick update on our progress toward our strategic priorities of accelerating growth, expanding operating margins, and transforming our portfolio.
At Envista, our focus is to partner with dental professionals to improve patients' quality of life by digitizing, personalizing, and democratizing oral care. We're committed to the dental community by spending a significant amount of time in the market, meeting with dental professionals to further understand their businesses, their workflows, and their needs. I just recently returned from a road trip where I met with over 100 customers across the U.S. While there is no doubt that talk of inflation and potential for an economic slowdown is weighing heavily on clinicians' mind as they look out over the next six to 12 months, it is also clear that currently patient traffic remains robust and dental professionals remain confident in the long-term prospects of the industry and their businesses.
Doctors in private and group practices continue to invest in their specialty treatments and are looking for ways to expand their capabilities, improving their workflows, and digitizing their offices. They see opportunity to enhance their efficiency and the predictability of treatments. DSOs remain committed to opening new offices, but are limited by supply chain and capacity constraints, including the lack of staff in dental offices. While we expect there may be additional uncertainties in the market short term, we continue to believe that the dental market is resilient and has ample room to grow over the long term. Turning to our Q2 progress with a uniquely positioned portfolio, our orthodontic business continues to deliver strong results. Our core bracket and wire business grew low single digit as a result of our differentiated Damon solution.
The new Damon Ultima System , which provides orthodontists more control for faster and more precise finishing, continues to gain share. This innovative solution commands a premium price by improving the way orthodontists move teeth. While we are proud of the strength of our bracket and wire business, it Spark Clear Aligner business that continues to accelerate rapidly. Again, delivering year-over-year core growth of over 100%. It initially took us three years to achieve 100,000 new Spark case starts. In the last six months, we have started an additional 50,000 cases, and we expect to further expand our position. The Spark solution is gaining momentum as we partner with top orthodontic professionals and clinics globally. In Q2, we were proud to sign a long-term agreement with Svět rovnátek , an orthodontic clinic based in the Czech Republic.
Svět rovnátek is a global leader in clear aligner therapy and is responsible for more clear aligner case starts than any other clinic in the world. This long-term partnership with a leading orthodontic clinic further validates the strength Spark Clear Aligner solution. our solutions for implant-based tooth replacement grew mid-single digits in the quarter. We continue to see robust growth in premium implants and our regenerative solutions. In addition to our strong commercial execution, we also signed two important agreements to further our mission of partnering with dental professionals to digitize, personalize, and democratize dental care. First, we entered into a long-term agreement with dentalcorp, North America's only publicly traded DSO. Based in Canada, dentalcorp has more than 500 offices and is a leader in the placement of implants in Canada.
Together, Nobel Biocare and dentalcorp have trained hundreds of clinicians and created a network that offers the latest tooth replacement solutions from Nobel Biocare. This agreement extends our partnership and further strengthened dentalcorp's ability to provide the highest quality of care to its patients. Earlier this month, we also announced that Nobel Biocare and Boston University will partner on philanthropic initiatives for the next decade. Through this partnership, Nobel Biocare will provide $4.4 million per year in products as in kind educational grant to Boston University's Henry M. Goldman School of Dental Medicine, GSDM. The students and residents at GSDM will have an opportunity to place and restore implants using this grant. This partnership will help us train the next generation of implant placers in North America.
In addition to driving growth and investing in our strategic initiatives, we remain intently focused on expanding our margins. In Q2 2022, we achieved an adjusted EBITDA margin of 19.7%. This represents a 40 basis point margin improvement versus Q2 2021. The Envista business system, EBS, and its focus on continuous improvement drives our execution. It helps us to offset and countermeasure the impacts of inflation and supply chain challenges while supporting our ability to invest for long-term sustainable differentiation and growth. In the quarter, we used EBS to drive discipline in pricing, achieving greater than 200 basis points of net pricing. Further, we took additional actions to streamline our organization and ensure that we can continue to invest in our strategic priorities while managing inflation and expanding our margins.
We optimize our regional organizational structure and delayered our operating companies to improve customer experience and provide us more flexibility as we move throughout the year. We're proud of the work we have done today and remain focused on further optimizing our operations to effectively deal with the challenging macro environment. While we expect persistent inflation-related concerns, supply chain challenges, and geopolitical issues to impact 2022 and beyond, we're confident that our continuous improvement culture rooted in EBS will allow us to deliver short-term results and invest in our long-term priorities. The transformation of our portfolio continues. The acquisition of Carestream Dental's IOS business has been successfully integrated into Envista, and we have relaunched the product under the DEXIS brand name. We intend to integrate the DEXIS scanner into our DTX platform to further simplify and optimize our specialty implant and ortho workflows.
During the period that we own this business in the second quarter, we achieved $5.5 million in revenue despite the lockdown in Shanghai that limited our ability to source the scanners. With the factory open since early June and the scanners now being built in bulk, we are well-positioned to drive above-market growth in second half of the year. We see significant interest from clinician and our distribution channel. The DEXIS IOS solution is well-regarded scanner, providing high performance and attractive price point. The 3,800 wireless scanner recently received a 2022 Red Dot Design Award that recognized its lightweight, convenient, and effective design. The jury specifically called out its balanced symmetry and minimalist elegance that is not only practical, but also a pleasure to operate.
With our attractive portfolio and robust R&D pipeline, we expect the DEXIS IOS solution to accelerate our growth and enable us to partner with clinicians to digitize, personalize, and democratize dental care. On July 5th, we closed the acquisition of Osteogenics Biomedical, a U.S.-based manufacturer of regenerative solutions. This acquisition is consistent with our strategy of focusing on the fastest-growing segments of the dental market and providing dental professionals with complete workflow solutions. Osteogenics is a well-respected company with a solid brand, a history of innovation, and strong ties to leading clinicians. This business is complementary to our implant offerings and will further position us as a leader in implant-based tooth replacement, and provides Envista a significant opportunity to create value for patients, our clinicians, and our shareholders. While we're excited about the strategic moves that we have made today, we see opportunities to further improve our portfolio.
We're committed to pursuing a disciplined approach to capital deployment. We utilize our EBS-driven M&A approach to manage a robust pipeline of inorganic partnership and investment and are actively cultivating new opportunities. I will now turn the call over to Howard to go through our second quarter financials and provide more details on our segment performance.
Thanks, Amir. Before we begin, I would like to remind you that our second quarter results are compared against prior year based on continuing operations, reflecting the sale of our KaVo Treatment Unit and instrument business as discontinued operations. On a reported basis, second quarter sales increased 1.3% to $645.8 million. Sales in the quarter were negatively impacted 3.6% due to foreign currency exchange rates, and acquisitions contributed 0.9% growth to reported sales. Core sales growth was 4% compared to the second quarter of 2021. Our year-over-year core sales growth reflects solid performance in our specialty Products & Technology segment, offset by weakness in our Equipment & Consumables segment.
Our Specialty segment delivered core growth of 9.6%, driven by solid performance in our implants and core bracket and wire businesses, and outstanding performance in our Spark Clear Aligner business. On a geographic basis, Western Europe delivered core sales growth of 11%, while North America increased 0.5%. North America was weighed down by its higher exposure to infection prevention and by modest destocking in our distributor channel. Our business in China was down 0.3% versus prior year due to the extended lockdowns in Shanghai. As expected, activity in China ramped up very quickly late in the quarter as Shanghai reopened. In Russia, we declined mid-single digit versus Q1 of 2021. This decline followed a strong Q1 driven by forward buying at the start of the conflict in Ukraine.
Outside of Russia and China, emerging markets continued to grow nicely off pandemic lows, up approximately 20% versus Q2 of 2021. Our second quarter adjusted gross margin was 58.7%, increasing by 40 basis points compared to the prior year due to higher volume and favorable mix, partially offset by the impact of inflation and our material costs. The adjusted EBITDA margin was 19.7%, which is approximately 40 basis points higher than Q2 of 2021, and in line sequentially. As previously discussed, in Q2, we continued to invest in our long-term innovation while increasing spend on travel and in-person customer-facing activities. Our adjusted EBITDA was also negatively impacted by one-time costs related to investments in our newly acquired DEXIS IOS business.
The overall investment was slightly lower than expected as we effectively redeployed available resources resulting from the KaVo divestiture towards the IOS business. In Q2, we also took actions to both eliminate the remaining stranded costs and further streamline our organization to ensure that we can continue to expand our margins while investing in long-term growth. Our second quarter adjusted EPS was $0.48 compared to $0.46 in the comparable period of the prior year. Our specialty Products & Technology segment core revenue increased by 9.6% compared to the second quarter of 2021, driven by solid growth in both our implants and core bracket and wire businesses, along with continued impressive growth from Spark.
In the second quarter, our combined orthodontic businesses grew 17% versus prior year, and with our core bracket and wires growing low single digits while Spark revenue continues to accelerate. Despite the toughening macro environment, we remain confident that our Spark business has immense potential to drive growth over the long term, and we are continuing to invest in order to capitalize on this opportunity. Our implant-based tooth replacement business grew mid-single digits in Q2 2022 versus Q2 of the prior year, driven by strong growth in all emerging markets, excluding Russia, with more modest growth reported in the developed markets. In addition to the growth in core implants, our regenerative business continues to accelerate. Our Specialty, Product & Technology segment adjusted operating profit finished at 22.8% in the second quarter.
This is down 120 basis points from Q2 of 2021, primarily due to the significant increase in investments to drive long-term growth, as well as the increase in customer-facing activities we participated in the quarter. Sequentially, we drove 40 basis points of margin improvement versus Q1 of 2022 in this segment. Our second quarter Equipment & Consumables segment core sales decreased by 4.7% compared to Q2 of 2021. While price positively impacted sales by approximately 4%, lower volumes across our imaging, restorative, and infection prevention businesses saw core sales drop compared to the second quarter of 2021. From a geographic perspective, growth was down in both developed and emerging markets. Our traditional imaging business declined mid-single digits in the quarter.
We saw very modest growth in North America offset by a meaningful decline in both Europe and China. Europe's weakness is attributed to inflation and uncertain macro environment complicated by the Russia-Ukraine conflict, while China was meaningfully impacted by the Shanghai lockdown. As Amir mentioned, our new IOS business delivered $5.5 million in the quarter, and we are very pleased with the outlook of this business. Clinicians remain very interested in investing in IOS solutions to help improve their overall workflow. Our restorative and endodontics business declined in the quarter, primarily driven by distributor destocking in North America and weakness in China related to the COVID lockdowns. Our business in Western Europe was up modestly and other emerging markets performed well in the quarter. As expected, sales of our infection prevention solutions continued to decline from elevated pandemic demand.
Despite the decline in revenue versus prior year, Q2 inventory sell-out trends reported by our distribution partners indicate that we are gaining market share in our core dental market. Further, we saw a sequential increase in revenue of over 25% versus Q1 of 2022. This supports our belief that sell-in and sell-out are more balanced and that this business should return to growth in the second half of 2022. Long term, we continue to expect this business to grow mid-single digits. Equipment & Consumables adjusted operating profit margin was 21.7% in the second quarter of 2022 versus 19.7% in Q2 of 2021. Solid margin improvement in imaging, restorative, and Infection Prevention solutions was supported by the increased price versus prior year.
These improvements were partially offset by material cost increases related to inflationary pressure on commodities and materials that impacted our businesses. Overall, the inclusion of the IOS business gives us confidence that our equipment consumables business will grow faster and be more profitable as we move forward. In the second quarter, we generated $11.9 million of free cash flow and ended the quarter with more than $500 million in cash after closing the Carestream Dental IOS acquisition. Free cash flow in Q2 was lower due to cash restructuring costs, transactional costs related to our acquisitions, timing of payments of certain incentive compensation, and increases in our accounts receivables related to the timing of customer order and payment patterns.
Overall, our balance sheet is very strong, and we have ample liquidity even after closing the acquisition of the IOS business in Q2 and the Osteogenics acquisition in early Q3. We have the flexibility to pursue additional inorganic growth opportunities when the right assets become available. Now, I'll turn the call over to Amir to discuss our outlook for the balance of the year and provide closing comments.
Thanks, Howard. While we are pleased with our performance here today and are confident about the long-term resilience of the dental market, we're mindful of macro environment and the related short-term challenges. Continued supply chain issues, persistent inflation, geopolitical risk, and the increased risk of additional severe COVID lockdowns in China are impacting the prospects of the second half of 2022. Given this background and increased downside risk to demand, we are updating our guidance for the balance of 2022. We now expect our core sales to grow mid-single-digit% for the full year 2022. Our newly acquired businesses, including both Carestream Dental IOS and Osteogenics, are expected to deliver 2022 sales of between $50 million-$60 million. We remain committed to achieving an adjusted EBITDA margin of 20% for the full year. Our priorities remain the same.
We will accelerate growth and expand our operating margins and further transform our portfolio through active and disciplined capital deployment. We're well-positioned to be the leader in both orthodontics and in implant-based tooth replacement. Our complete workflow offerings, including our imaging and diagnostic solutions, will improve the productivity of dental professionals while empowering them to provide personalized and predictable treatments for each patient. Our EBS heritage and focus on continuous improvement will allow us to consistently deliver results while investing to build sustainable competitive advantage. Our purpose is to partner with dental professionals to improve patients' life by personalizing, digitizing, and democratizing dental care. We're focused on delivering long-term value for patients, our customers, our employees, and our shareholders.
Thanks, Amir. That concludes our formal comments. We are now ready for questions.
At this time, if you would like to ask a question, please press the star and one keys on your touch tone phone. You may remove yourself from the queue at any time by pressing the pound key. Once again, that is star one to ask a question. Our first question will come from Elizabeth Anderson with Evercore ISI. Your line is open.
Hi, guys. Thanks so much for the question. I guess my first question, thanks for all the color on the drivers of the different segments and product areas in the quarter. I think, you know, one of the key questions I've been thinking about, you know, with the uncertain macro environment out there is, you know, sort of as we were wrapping up Q2 and maybe into Q3, can you sort of go through how you sort of see market, you know, volumes in the different areas and implants and orthodontics, et cetera, in terms of the back half of the year?
Yeah, happy to do that, Elizabeth. Thank you. What we are seeing, as I mentioned, we have been traveling and talking to a large number of our customers and customers that they're not currently buying from us. What we are seeing is overall outlook is very positive. In fact, latest visits were with 100 oral surgeons. Some of them are telling us that we have patients booked up to about October. You have this challenge of specialists continue to see a ramp and continuation of a patient flow. That's what we have been seeing. On implant placement, we see that a continuation of the growth as we go forward, and we are confident that what we are offering really meet the requirements. The same thing on orthodontists.
We got to keep in mind what we are offering is really different than what the norm look like. We are very focused on a small number of orthodontists that they are, that's all they do. They start the treatment by getting a CBCT, understanding the patient anatomy before they offer any type of solutions. If you look at that segment, we continue to see momentum, and it starts moving forward and as we have demonstrated that in Q2 as well. On the other hand, three macro events are really impacting the risk, and that's why a change in guidance moving forward. Top of the list is inflation. Increased rates is weighing heavily on capital equipment, investment in the long run.
We saw somewhere between 25%-30% reduction on inventories in the channel between end of Q2 to beginning of Q1. That's one really important factor to see in here, capital equipment as well as inventory reduction. We think the European economy and risk associated with the energy supply is going to weigh heavily in this industry. Right now, as expected, Europeans are on vacation and the forecast, what we see after September, is just not as clear as what we have seen in the past. We're waiting for dust to settle to see where this ends up. Last but not least is a slower recovery in China. There is additional severe lockdown risk of lockdowns. In order to put all of this together, about 14%-15% of our business is Russia and China.
Unpredictable, we're not sure exactly where it's gonna end up. We've got the European challenges ahead of us. In North America, what we are seeing, a continuation of a growth both on a DSO as well as the specialists. We're trying to balance all of these and make sure that we land in a place that we can continue to make investment, deliver margin, see, in the long run, the growth opportunities, and make sure that we come out of this situation much stronger as we did in 2022. That's a little bit of a perspective and macro view that we have on the market with value segment and how we are managing our investment and priorities.
That's super helpful. Maybe one for Howard or you could answer as well. You mentioned the distributor destocking in the quarter. Could you give us a little bit more color on sort of like what happened with the sort of destocking there, and then also how long you expect that to last and sort of be over?
Yeah, I can answer that, Elizabeth, as well. I mentioned about 25%-30% reduction, but let me provide some color into it. About 85% of our overall portfolio are consumables. Only about 15%, what we call equipment of about $5,000-$10,000. Those equipment, normally distributors do not keep any stocking. They place an order, we deliver it directly. The other areas, the other traditional consumable as well as the Infection Prevention, the natural inventory that distributors keep in Europe, U.S., other geographies, have come down, as I mentioned, 25%-30% during the quarter. Obviously, they are preparing to deal with uncertain environment, they're preserving cash. But also there is a proxy at play, as Howard talked about Infection Prevention.
Our expectation is now with the position that we have known all along, the sellout and selling match, we have a really good visibility on it. Those are some of the challenges that we are dealing with as we go. We dealt with it in Q4, we're dealing with it as we go forward. We think this managing distribution tightly, managing inventory tightly is becoming the norm, at least in the short term, until there is a little bit of a clarity over the long-term horizon.
Got it. Thank you.
Thank you. Our next question will come from Jeff Johnson with Baird.
Thank you, guys. Good afternoon. Can you hear me okay?
Yeah, we can hear you, Jeff. Go ahead.
All right. Yeah, great, Howard. Thank you. I'm in a car, so I just wanted to make sure. Just a couple questions here. Amir, when I look at your updated guidance, it looks like you're kind of guiding to very similar mid-single-digit core growth at a company-wide level over the second half. That's almost exactly what you delivered in the first half. You know, obviously, you just laid out three or four things in the quarter and going forward that you're a little more concerned about. How do you keep up that kinda mid-single-digit growth that seems to be implied in your updated guidance for the back half of this year against what seems to be pretty stable comps? Is that as the destocking comes off, as China comes back, those help offset some of your other concerns?
Is it kind of as simple as that?
You're absolutely correct. We expect to see a little bit of uptick in second half versus the first. The reason for it is, take a look at our businesses. We are confident that the ortho business is going to continue to progress and get better as we go forward. We think that momentum that we have seen on Spark, the number of active doctors are ramping up, we're signing up new doctors. Spark growth is just something that we are building capacity, have continued to build capacity. That acceleration of growth is something that we are expecting to be an ongoing for years to come, not only second half. We expect to see, first half was negatively impacted by two elements.
One was the China issue, and we are assuming that there is no more lockdown in second half. If that happens, then we gotta deal with it as it comes. Also the IPS, our Infection Prevention, had in the first half the core growth was negatively impacted by about 200 basis points due to Infection Prevention inventory correction. That's another positive thing that we are seeing in second half. The rest of our business, implant placement continues to make progress. We are fairly confident that that will move forward. Exactly as you said, we are trying to kind of manage this, knowing some of this uncertainty. That's why we think mid-single-digit is really relevant, given where we stand today.
Hey, Jeff, this is Howard. Maybe one other addition there. I think that we're encouraged by some of the traction that we're seeing in pricing as well. You know, over each of the last two quarters, we're seeing some greater traction and on the pricing front, and we anticipate that will continue also here in the second half.
Yeah, that's helpful, Howard and Amir both. Howard, that was segued right into my follow-up question that I wanted to ask on pricing. The +2% this quarter, how does that compare in Q2 versus Q1? I think you took another round of increases April 1, so just what was it in Q1 versus the +2% this quarter? Do you see that staying at +2% the rest of this year, or does that tick higher throughout the year? Thank you.
Thanks, Jeff. We did actually see an incremental step up in our pricing traction in the second quarter. We've seen even in the first quarter, we saw a step up from what we saw in the second half of last year as well. You know, the process is in place, and we feel good that each of the opcos are taking a systematic approach, realizing some of the inflationary factors to be considered, as well as ensuring that we're growing with the market or better than the market in each of those areas. I think for the second half, we're gonna continue to see that traction and probably even a little bit of a step up, as you indicated, Jeff.
We've had a couple of different price increases, and we think that those will hold into the second half as well.
All right. That's great. Thank you.
Sure.
Thank you. Our next question comes from Jon Block with Stifel. Your line is open.
Good afternoon.
Hey, Jon.
Hey, hey, Howard. Maybe just for the first question, Amir, and sorry if you may have touched on this, but just talk to us on how trends played out throughout the second quarter. You know, we're getting some of that, like April might've had catch up from Omicron, and then there was a wave that might've hit some traction in June. Would just love your thoughts on how Q2 progressed. Then Howard, sort of tack onto that, just anything on the cadence for Q3 or 4Q. I mean, obviously, mid-single digit top line for the year, and that was sort of the number in H1.
Should we just think about growth being linear throughout 2022, or is there any sort of fluctuation between Q3, Q4 as we adjust models for the back part of the year? I've just got a follow-up.
Okay. Let me answer the Q2 thing. China lockdown. China did not open, Shanghai did not open till early June. March, April, most of March, April and May, we basically had very limited business to very end of the quarter. It was not linear at all. We had orders in our hand, we had customers waiting, and the last three weeks of the quarter, four weeks of quarter, we were able to really catch up and make sure that those appointment are not canceled, people have equipment in their hand, tools in hand. The other part of this, we're talking about the Q2 specifically, areas such as consumable business as well as Spark Clear Aligner and Ortho, we did not see any major changes in the ramp, the continuation.
We saw a little bit of a change in the inventory, but not on the sellout on traditional consumable or a Spark or bracket and wire. What we did see a step down on equipment started a little bit stronger and it start becoming slower and slower as we went forward throughout the quarter. I think it was a continuation of the news in the market, a little bit of a conservatism on the part of investors, as well as some challenges on opening the new de novos, resources, simply getting building the capacity that they need.
Simple answer in Q2, we did not see that linearity that we had become kind of accustomed to, but it varies by segment, it varies by geography. As we started looking at those, tried to kind of countermeasure and manage it throughout the quarter. Now for the rest of the year.
Yeah. Jon, I would say that as it relates to phasing in the second half, you know, typically our Q3 quarter is a little bit lighter just from a phasing standpoint, with the, you know, holidays taken in much of Europe during that period as well. We do see that we'll grow mid-single digits here in the third quarter. A little bit heavier growth probably in the fourth quarter, and that will also be true of our profit profile. We think that our EBITDA, adjusted EBITDA margins will be slightly stronger in the fourth quarter than in the third, just because the volumes are substantially larger in the fourth quarter. That's our point of view today.
Got it. Very helpful on the phasing. Then just Amir, just taking a step back, I'd love your thoughts on, you know, the IOS business. Maybe just talk to us. You announced a deal around year-end. I think it closed in April, and then here we are arguably, whatever, three months later. A lot's gone on in the world over the past seven or eight months.
Yeah
the world, and I think even specifically the IOS market. You know, where do you stand today? What have you guys achieved in terms of maybe the early wins that you wanted to capture with the deal and the integration? How do you feel on this, you know, going forward, when you think about your long-term growth rates and goals with the business?
Yeah. Thanks, Jon. We have a hypothesis that has not changed at all in that regard. We knew the market was about $1 billion, growing double digits. We knew and has been validated that it is less than 15% penetrated, and it's penetrated on various geographies, various segments. For example, those that do clear aligner, majority of them, they do have one. But in many other segment, IOS is really not that penetrated. We knew also that there is significant price differentiation, and it is really obvious point solution versus fully integrated complete solution on how these systems were working in an open environment versus a closed environment. I know that you know what I'm referring to. Receiving file from others, sending file to others versus just being a closed system selling those.
We knew a lot of that. It was validated. We did a lot of due diligence before we entered the market. After the close, we selected, and we knew exactly we needed to do three things. The number one thing that we wanted to do was expansion of the channel. Carestream IOS has less than 10% market share, and it's an awesome product, over 30% EBITDA margin. Whoever we talked to, they said the product is really good. The infrastructure for support, expanding it worldwide was just not there, specific in geographies like in the U.S.
We knew by going to a hybrid model, like putting that part of our ortho implant business as well as putting in our channel, we would take the first step in at least making it available to people who wanted to buy it. So far, we have seen good uptake. The second part of this was about operational improvement. Even though it has a really strong reputation, we wanted to improve the operational capabilities, improve gross margin, reliability. Here we have taken the first step, but as you can imagine, the lockdown has really limited our ability. We have built now a service support capabilities around it. We're looking at the demos that exist everywhere to make sure that they're up to date and up to speed. We're gonna continue to work on it.
This is the hallmark of EBS and what we stand for, and I think we can do a lot better job in here. Last part is about portfolio and R&D. It has a robust hardware. It has a software that it is a really good software today, but we need to integrate it into DTX. We need to integrate it into our workflows, and we are working on it to make sure that this is gonna happen as quickly as possible. We got a great product in an awesome market, good price performance, in a better channel now, with a better productivity and with the R&D backing it. We think, you know, we got something in our hand that is gonna enable us not only grow the IOS by itself, but help our specialty businesses in the long run.
We're really pleased with what we have done in here so far and expect great growth over time as an outcome of this acquisition and integration.
Amir, if I can just quickly ask a clarification question. I think last quarter you had IOS contributing $35 million-$45 million for the rest of the year. I think you now said both businesses, I believe, including Osteo, is $50 million-$60 million. One, is that correct? Two, did the underlying IOS change, you know, up or down in any way? Thanks, guys.
Yeah. No, you're absolutely correct. Those numbers are absolutely right. $35 million-$45 million IOS, about $5.5 million in Q2 since we owned it. We think that Osteogenics is about $15 million for rest of the year. So you add them up, $50 million-$60 million growth in core part of our business. Obviously, when we take a look at the growth versus core growth, they're not being considered as part of our core growth until about a year after acquisition. But they are really changing the format, the mixture of our business going forward. The IOS by itself is gonna add about 50 basis points of growth in the long run, about 30-40 basis points of margin. Osteogenics acquisition is almost doubling the size of our biomaterial.
Just give you a little bit of a feel for it. For every implant that is placed, 75%-80% of them, they either need a bone rebuild or a membrane. If you look at the price ratio, it's about a 5:1. For every $5 of implant, every $1 of implant, you normally sell 20%-25% of the biomaterial. We have been so under index in that area. We're less than 10%, even with Osteogenics. Now we have an opportunity to really ramp that up. We got about a $900 million-$1 billion worth of implant business and very small presence in biomaterial. Combination of these two acquisition really puts us in a different place as we go forward.
All good. Thanks for the color.
Thank you, Jon.
Thank you. Our next question will come from Michael Cherny with Bank of America.
Good afternoon, thank you for all the color so far. I wanna think a little bit, maybe more on a medium-term basis, call it 18 months or so, or 24 months. As you think about your R&D efforts, especially given strength, depth and Spark integration on DEXIS IOS as examples, how do you think about the bifurcation of products over time? The reason I'm asking this is, as all the themes of this call have been, clearly, there's a level of uncertainty that's coming into the market regarding current end market demand. There's also pieces of uncertainty that continually come up relative to potential for trade-down in various different areas of the economy.
How do you feel as of right now, both in terms of what you have and what you have in the pipeline, Envista's position to be able to bifurcate both the high end and low end of all the different end markets you play in?
Thanks, Mark. I'm gonna point to the past two to three years first before I answer that question. We started coming out of Danaher with about a 50% equipment consumable, you know, being exposed to a lot more distribution, heavy equipment. In the past two years, we have completely shifted our portfolio. It took about a 5% of our business in 2020. We basically moved away from it. We sold the KaVo Treatment Unit and Instrument and another $400 million business. We put ourselves. If you look at exposure to market, we put ourselves in a very different place. A couple of acquisitions has put us in a lot more specialty, a lot more direct, higher margin business, and that's what we're gonna continue doing.
Okay, upon saying that, the question is, what are we gonna do in the next 18 months? Our long-term view of becoming the leading ortho provider with the combo treatment of a bracket and wire, as well as Spark Clear Aligner, has not changed at all. We think that that combination provides unique differentiation, both from a pricing as well as finish, as well as quality of what we provide, the network that we have, the exposure that we have worldwide. We're not backing off at all in any of those investment. We're being very prudent, long term versus short term, and that is space. When we look at our implant placement part, we have made significant progress on the premium side. A lot of it has been, honestly, due to commercial execution. TiUltra and Xeal, the surfaces have made a huge difference in there.
Nobel Biocare N1 is gonna make a huge difference in the long run. We're not counting on a whole lot of new R&D to come in here and change the model as we go forward. Execution, EBS at the core of what we do, we have an opportunity to really ramp up our value implant organically as well as inorganically to build that segment to become an important part of our growth going forward. As I mentioned, we have really shifted our traditional equipment to be part of the overall of what we offer, an end-to-end solution. From a R&D perspective, we have been very thoughtful on doing things not because we wanna be an equipment provider, but doing things that allows us to optimize the entire workflow. That's why we are putting so much energy on software and integration, open architecture platform.
We prefer people buy our product, but regardless, if you wanna use other company's product, we still wanna improve productivity and predictability of dental offices, DSOs, group practices, universities. We're being thoughtful on where to invest, how to manage this. Short answer, in the long run, I think we have a clear eye toward 2023, 2024, 2025, and we think the approach that we have taken in the past several years is gonna help us to become a much better company from a growth margin perspective and truly differentiate it that practitioners wanna do business with and partner with for the long run.
Thank you, Amir. Then just one more quick follow-up. I think I know the answer to this, but obviously, you've talked about a lot of short-term variability. Any changes whatsoever to the long-term targets you laid out back in April at the Investor Day?
No, not at all. We think that high single-digit growth is very much within reach. We have said that 2025 we wanted to be high single-digits plus, all the years, double-digit growth, get our EBITDA to be 22.5%-23%, 50-75 basis points of growth. We don't think anything has changed in the short term that moves our position from that long-term commitment and perspective.
Great. Thanks so much.
Of course.
Thank you. Our last question will come from Nathan Rich with Goldman Sachs.
Hey, good afternoon, Amir and Howard. Thanks for taking the question. I guess just trying to tie things together, it seems like there were really three things that had a pronounced impact on sales in the second quarter: the lockdowns in China, the pull forward you mentioned of sales in Russia into the first quarter, and the destocking effects. I guess, is it possible to quantify the impact that those three items had on second quarter performance, just as we think about the more normalized run rate of the business and how it performed in the second quarter? You know, I think one of the things that really stood out was the performance of the specialty segment.
Amir, you talked about the strong volumes the specialists are seeing and traction that you've made in the DSO and large group practices. I guess, how do you feel about your ability to continue to drive demand for your specialty portfolio, in a softer market backdrop, especially if that persists, for a longer period of time? Thank you.
Maybe, Nate, I take the first part of that question, then Amir can take the second. I would say as it relates to China, as Amir indicated, you know, those lockdowns went substantially longer than we had anticipated. I think we said that the growth in China in the quarter was relatively flat, slightly down, I believe. That's a business that we've historically seen and grow double digits. If you think about it in that context, that's probably, you know, a point of overall growth impact to the quarter.
I would say in Russia, you know, if you normalize the first half, it's probably reasonable, i.e., you know, it at the beginning of the conflict there was a substantial buildup and pull-in of, you know, customer-generated orders that came in the first quarter that subsided here in the second quarter. On an aggregate basis, first half, I think that's probably totally reasonable. Lastly, in terms of the destocking, I mean, there are a couple of different factors going on there. One of them is, and when we talk about the Infection Prevention, clearly continue to destock. We feel as though the sell-in is healthy and we're actually gaining market share.
For that reason, we have confidence that that's gonna turn around and we're gonna see some growth as it relates to the Infection Prevention here in the second half. I think that we saw a little bit of weak takedown in the inventory side as it relates to the resto business as well by a few of our large distributors. Should have been worked out and we see that, you know, in the second half that we get back to normal growth as well.
Nate, answer your question, how do we generate demand? Let me just give you some statistics in here, maybe that would be helpful. In Q2, the sequential growth for Spark was 27.8% on just production output, cases shipped. If you look at new doctors, close to about almost double-digit new doctors being added. Active doctors, double-digit, just keep adding to what they have been doing. Keep adding new doctors. Those that they are in there continue to do more and more cases. We are seeing that trend to continue. There's nothing in there that has caused us to change our views on that product category. If you look at our traditional bracket and wire, three years prior to COVID, it was growing mid-single-digit. We have seen a similar performance.
The Damon Ultima is really making a difference. Our Orthodontic overall franchise is doing a really good job continuing to make progress, taking share. Because of the segment that we are focused, because of how we go to market, and the training education. Now come back on the implant side. Majority of customers that we deal with, they're looking for a way to place more implants utilizing the same assets that we have, they have. If you look at DSOs, they wanna place more implants. You go to some of these group practices, they wanna do more full arch. That is possible through digitization, using guided navigated surgery, using AI, using simulation. The way to generate demand is protect your current base, expand what they are doing, and start going after your competitors.
That current base that we have, if they just continue to do more, which is what they wanna do, gives us confidence in what we see on the demand generation going forward. We have expanded our traditional consumable reach, signing up additional distributors in Europe and other geographies. Given what we have now on the equipment, and specifically with IOS, gives us more leverage to go to various distributors, selling directly as well as selling through distributors. Combination of all of that's how we feel comfortable that that demand generation expansion is gonna continue as we go forward.
Thanks. That's really helpful. If I could just sneak in one quick follow-up for Howard. You know, on the margins, you know, you guys always, I think, operate with expense discipline. You mentioned, you know, the commitment to the 20% EBITDA margin this year, and you took some streamlining actions, I guess, in the quarter. Could you maybe quantify the magnitude of savings that you expect from those actions? And is there anything else planned over the balance of the year as we think about margin cadence and getting to that 20% margin for the year?
Yeah. Nate, we have confidence that we'll take the actions required to go ahead and deliver that and land this thing at 20%, despite making committed long-term investments. As Amir's mentioned, we will continue to fuel these growth initiatives and ensure that we're able to achieve those long-term targets that we talked about earlier. As it relates to some of these actions, I mean, we take them across different areas as well. Again, overall on the balance, we believe that we'll be able to hit the 20% adjusted EBITDA margin for the full year. Thanks, Nate.
Thanks very much.
I think that's all. I think we're out of time here, so I really appreciate everyone for tuning in today. Thank you so much. If you have any other questions, please feel free to reach out to us, and we're happy to schedule calls offline as well. Thank you so much, and have a great rest of your day.
Thank you, ladies and gentlemen. This concludes today's conference call, and we appreciate your participation. You may disconnect at any time.